Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01829932
Recruitment Status : Completed
First Posted : April 11, 2013
Last Update Posted : October 14, 2015
Sponsor:
Information provided by (Responsible Party):
Dr. Stephen Vanner, Queen's University

Brief Summary:
Irritable bowel syndrome (IBS) is a chronic gastrointestinal illness of unknown cause whose symptoms include abdominal pain, bloating and altered bowel pattern. Diet has been shown to influence the bacteria gut interaction. Our aim is to determine if components of the diet affect IBS symptoms by changing the bacteria gut interaction. In particular, we will measure whether after being on a diet high or low on certain factors there is a change in the timing and amount of hydrogen and methane produced by bacteria digesting lactulose and on IBS symptom severity.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Dietary Supplement: Factor Altered Diet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study
Study Start Date : April 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Active Comparator: High Factor Diet
Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
Dietary Supplement: Factor Altered Diet
Active Comparator: Low Factor Diet
Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
Dietary Supplement: Factor Altered Diet



Primary Outcome Measures :
  1. Area under the Curve of Hydrogen Gas on Lactulose Breath Test [ Time Frame: 5 hours ]

Secondary Outcome Measures :
  1. Change in Area Under the Curve on Lactulose Breath Test from Baseline [ Time Frame: 5 hours ]
  2. Change in IBS Symptom Severity Score from Baseline [ Time Frame: 3 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet Rome III criteria for IBS
  • Willing to undergo dietary intervention

Exclusion Criteria:

  • History of Gastric, Small Bowel or Colonic Surgery
  • History of Inflammatory Bowel Disease
  • Celiac Disease
  • Unable to come off following medications: antibiotics, laxatives, narcotics, sedatives
  • On a pre specified diet
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829932


Locations
Layout table for location information
Canada, Ontario
Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Investigators
Layout table for investigator information
Principal Investigator: Stephen Vanner, MD, FRCPC Queen's University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Stephen Vanner, Professor of Medicine, Queen's University
ClinicalTrials.gov Identifier: NCT01829932    
Other Study ID Numbers: DMED-1443-11
First Posted: April 11, 2013    Key Record Dates
Last Update Posted: October 14, 2015
Last Verified: October 2015
Keywords provided by Dr. Stephen Vanner, Queen's University:
Diet
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Syndrome
Disease
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases